Compare · AMRO vs EW
AMRO vs EW
Side-by-side comparison of Amaero Inc. (AMRO) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- AMRO operates in Industrials, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $58.73B, about 452.2x AMRO ($129.9M).
- EW has hit the wire 8 times in the past 4 weeks while AMRO has been quiet.
- EW has more recent analyst coverage (25 ratings vs 0 for AMRO).
- Company
- Amaero Inc.
- Edwards Lifesciences Corporation
- Price
- -
- -
- Market cap
- $129.9M
- $58.73B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Amaero Inc.
Amaero Inc. is a leading U.S.-based producer of high-value refractory and titanium alloy spherical metal powders for additive manufacturing ('AM') and advanced manufacturing, and a pioneer in Powder Metallurgy Hot Isostatic Pressing ('PM-HIP') manufacturing of large near-net-shape components. With manufacturing and corporate headquarters in Tennessee, we occupy a strategically critical position at the intersection of U.S. national security priorities, including the rebuilding of a more resilient and scalable defense industrial base and the reshoring of sovereign manufacturing and supply chains.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest AMRO
No recent items for Amaero Inc..
Latest EW
- Edwards Lifesciences upgraded by Robert W. Baird with a new price target
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Third Quarter Results
- Edwards Lifesciences upgraded by Truist with a new price target
- CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System
- Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features
- FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease
- CVP, TAVR Lippis Daniel J. sold $53,017 worth of shares (619 units at $85.65) as part of a pre-agreed trading plan (SEC Form 4)
- Barclays initiated coverage on Edwards Lifesciences with a new price target